OPRX: OptimizeRx Corp.
About
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.
Current Value
$4.071 Year Return
Current Value
$4.071 Year Return
Key Details
Market Cap
$75.16M
P/E Ratio
-3.08
1Y Stock Return
-58.02%
1Y Revenue Growth
40.40%
Dividend Yield
0.00%
Price to Book
0.7
Strategies that include OPRX
Stock's related to OPRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| KBR | 44.53% | $7.77B | +11.73% | 1.00% |
| TRC | 43.18% | $424.34M | -2.47% | 0.00% |
| PHR | 41.14% | $1.07B | +20.61% | 0.00% |
| FOUR | 40.01% | $7.17B | +60.36% | 0.00% |
| IDXX | 37.90% | $34.09B | -12.85% | 0.00% |
| MCFT | 37.18% | $344.65M | -0.29% | 0.00% |
| WSBF | 36.87% | $295.44M | +27.51% | 3.93% |
| ULH | 36.64% | $1.25B | +97.14% | 0.88% |
| FLIC | 36.38% | $312.91M | +21.97% | 6.05% |
| VPG | 36.17% | $279.20M | -30.23% | 0.00% |
| TMCI | 35.95% | $483.43M | -8.71% | 0.00% |
| TY | 35.50% | - | - | 3.32% |
| HCAT | 35.28% | $458.79M | 0.00% | 0.00% |
| SAIC | 35.05% | $5.92B | +3.71% | 1.24% |
| NVEC | 34.96% | $364.49M | +7.38% | 5.30% |
| SLP | 33.89% | $554.26M | -28.05% | 0.66% |
| ONEW | 33.56% | $281.57M | -26.61% | 0.00% |
| LDOS | 33.50% | $21.12B | +49.80% | 0.96% |
| TITN | 33.45% | $323.79M | -47.25% | 0.00% |
| PGEN | 33.20% | $228.91M | -28.00% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PG | -<0.01% | $402.15B | +14.14% | 2.33% |
| LFVN | 0.06% | $169.84M | +130.61% | 1.10% |
| QFIN | -0.07% | $5.09B | +95.80% | 3.47% |
| BRO | 0.13% | $31.27B | +47.55% | 0.49% |
| VSTM | 0.16% | $176.25M | -36.94% | 0.00% |
| MNST | 0.18% | $52.25B | -1.95% | 0.00% |
| FDP | 0.18% | $1.62B | +45.67% | 2.97% |
| QNRX | 0.18% | $3.20M | -85.07% | 0.00% |
| TGS | 0.20% | $1.97B | +116.04% | 0.00% |
| XOM | -0.23% | $521.39B | +13.56% | 3.22% |
| GL | -0.26% | $9.18B | -8.60% | 0.86% |
| EH | 0.32% | $689.36M | +1.82% | 0.00% |
| HRL | -0.40% | $16.30B | -8.38% | 3.81% |
| CPSH | -0.43% | $20.70M | -40.13% | 0.00% |
| WMT | 0.43% | $696.11B | +66.69% | 1.38% |
| UNH | 0.44% | $531.00B | +6.93% | 1.37% |
| KSPI | 0.45% | $20.86B | +18.06% | 3.37% |
| SMPL | -0.46% | $3.81B | -3.16% | 0.00% |
| MRO | 0.47% | $16.08B | +13.59% | 1.53% |
| LW | -0.48% | $10.70B | -23.51% | 1.93% |
ETF's related to OPRX
News
Yahoo
WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professional (HCPs) and patients, today announced that management will participate in the following upcoming investor conferences: 13th Annual ROTH Technology Conference, New York City, November 19th – 20th, 2024Canaccord Genuity’s 2024 CG MedTech, Diagnostics and Digital Health & Servi
Yahoo
OptimizeRx Corp (OPRX) reports strong revenue growth and AI advancements, but faces hurdles in DTC transition and net loss impacts.
SeekingAlpha
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2024 Results Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsWilliam Febbo - Chief...
Yahoo
OptimizeRx (OPRX) delivered earnings and revenue surprises of 100% and 14.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
- Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to $13.4 million with a gross margin of 63% - Won 5 DAAP deals during Q3 WALTHAM, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, reported results for the three months ended September 30, 2024. Quarter
Finnhub
OptimizeRx Reports Third Quarter 2024 Financial Results - Q3 revenue of $21.3 million, increasing 30% year-over-year - Q3 gross profit increased 37% year-over-year to...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.